PFE: Flat Q3 revenue masked growth outside COVID-19 products as impairments pressured 9M earnings

What happened

Pfizer's third-quarter revenue was broadly flat. Excluding Comirnaty and Paxlovid, revenue grew 7% on an operational basis, which means before currency effects. Adjusted earnings per share, or profit per share after certain adjustments, held at $0.87. Nine-month earnings were weighed down by impairments and legal costs.

Confirmed

Global impact / market context

The flat headline hides that the core business outside COVID-19 products is growing, while impairments, which are write-downs in the value of assets, and legal costs drag reported earnings. Cost-saving programs and pipeline investment decide whether profit per share recovers as COVID-19 product sales fade.

Analyst inference

Investors comparing Pfizer with peers will focus on growth excluding COVID-19 products rather than the flat total. Sustained cost savings and pipeline spending shape future revenue and costs, while impairments and legal charges show how write-downs and litigation can pressure reported earnings even when adjusted profit per share is stable.

Analyst inference

What to watch

1. Watch whether quarterly revenue keeps growing outside Comirnaty and Paxlovid, since that 7% operational growth, which means before currency effects, is the clearest sign of underlying demand. Confirmed
2. Track progress of cost-saving programs and pipeline investment, as management presents them as central; savings would lower costs while pipeline spending raises them near term. Proposed
3. Watch for further impairments and legal costs in nine-month earnings, because these items can lower reported profit even if adjusted earnings per share stays stable. Analyst inference

Evidence

• Original source link unavailable